APA (7th ed.) Citation

Kreuter, A., Rasokat, H., Klouche, M., Esser, S., Bader, A., Gambichler, T., . . . Brockmeyer, N. H. (2005). Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Investigation, 23(8), 653. https://doi.org/10.1080/07357900500358259

Chicago Style (17th ed.) Citation

Kreuter, Alexander, Heinrich Rasokat, Mariam Klouche, Stefan Esser, Armin Bader, Thilo Gambichler, Peter Altmeyer, and Norbert H. Brockmeyer. "Liposomal Pegylated Doxorubicin Versus Low-dose Recombinant Interferon Alfa-2a in the Treatment of Advanced Classic Kaposi's Sarcoma; Retrospective Analysis of Three German Centers." Cancer Investigation 23, no. 8 (2005): 653. https://doi.org/10.1080/07357900500358259.

MLA (9th ed.) Citation

Kreuter, Alexander, et al. "Liposomal Pegylated Doxorubicin Versus Low-dose Recombinant Interferon Alfa-2a in the Treatment of Advanced Classic Kaposi's Sarcoma; Retrospective Analysis of Three German Centers." Cancer Investigation, vol. 23, no. 8, 2005, p. 653, https://doi.org/10.1080/07357900500358259.